Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression
The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Dyslipidemia observed in type 2 diabetes (T2D) is atherogenic. Important features of diabetic dyslipidemia are increased levels of triglyceride-rich lipoproteins and small dense LDL particles, which all have apolipoprotein B100 (apoB100) as a major apolipoprotein. This prompted us to study the effect of the GLP-1 agonist liraglutide on the metabolism of apoB100-containing lipoproteins. RESEARCH DESIGN AND METHODS: We performed an in vivo kinetic study with stable isotopes (L-[1-13C]leucine) in 10 patients with T2D before and after 6 months of treatment with liraglutide (1.2 mg/day). We also evaluated in mice the effect of liraglutide on the expression of genes involved in apoB100-containing lipoprotein clearance. RESULTS: In patients with T2D, liraglutide treatment significantly reduced plasma apoB100 (0.93 ± 0.13 vs. 1.09 ± 0.11 g/L, P = 0.011) and fasting triglycerides (1.76 ± 0.37 vs. 2.48 ± 0.69 mmol/L, P = 0.005). The kinetic study showed a significant increase in indirect catabolism of VLDL1-apoB100 (4.11 ± 1.91 vs. 2.96 ± 1.61 pools/day, P = 0.005), VLDL2-apoB100 (5.17 ± 2.53 vs. 2.84 ± 1.65 pools/day, P = 0.008), and IDL-apoB100 (5.27 ± 2.77 vs. 3.74 ± 1.85 pools/day, P = 0.017) and in catabolism of LDL-apoB100 (0.72 ± 0.22 vs. 0.56 ± 0.22 pools/day, P = 0.005). In mice, liraglutide increased lipoprotein lipase (LPL) gene expression and reduced proprotein convertase subtilisin/kexin type 9 (PCSK9), retinol-binding protein 4 (RBP4), and tumor necrosis factor-α (TNF-α) gene expression in adipose tissue and decreased PCSK9 mRNA and increased LDL receptor protein expression in liver. In vitro, liraglutide directly reduced the expression of PCSK9 in the liver. CONCLUSIONS: Treatment with liraglutide induces a significant acceleration of the catabolism of triglyceride-rich lipoproteins (VLDL1, VLDL2, IDL) and LDL. Liraglutide modifies the expression of genes involved in apoB100-containing lipoprotein catabolism. These positive effects on lipoprotein metabolism may reduce cardiovascular risk in T2D.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vitro studies further showed that liraglutide directly reduced the expression of several genes involved in chylomicron production and of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene [40, 42].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [42]
In the citing paper
“Liraglutide has also been shown to significantly modify lipoprotein metabolism, with a reduction of chylomicron production [40, 41] and an increase in chylomicron and low-density lipoprotein (LDL) catabolism [40, 42].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [42]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708
Self-citationOverproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Cited by
Ghodsian, N., Abner, E., Emdin, C. A., Gobeil, É., Taba, N., Haas, M. E., Perrot, N., Manikpurage, H. D., Gagnon, É., Bourgault, J., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100437 · Cited by 229
The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Packer, M. (2025) · JACC · doi:10.1016/j.jacc.2025.06.055 · Cited by 173
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 175
“Treatment of 10 subjects with T2D (average age 48.6 years) with 1.2 mg liraglutide daily for 6 months reduced ApoB48 levels and ApoB48 production rate and enhanced the catabolic rate of ApoB48 (determined via D 8 -valine isotopes), findings independent of body weight loss (32, 33).”
InfluentialVergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
“Liraglutide has also been shown to significantly modify lipoprotein metabolism, with a reduction of chylomicron production [40, 41] and an increase in chylomicron and low-density lipoprotein (LDL) catabolism [40, 42].”
BackgroundSelf-citationCherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus
Bonilha, I., Hajduch, É., Luchiari, B., Nadruz, W., Goff, W. L., & Sposito, A. C. (2021) · Metabolites · doi:10.3390/metabo11120807 · Cited by 62
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Saraiva, J. F. K., & Franco, D. R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01417-0 · Cited by 41
“Studies in mice and humans showed that GLP-1 liraglutide acts directly and indirectly in LDL and VLDL catabolism, increases lipoprotein lipase gene expression responsible for TAG hydrolysis, and reduces apolipoprotein B48, diacylglycerol O-acyltransferase 1, and microsomal transfer protein gene expression, all of whic…”
BackgroundEffect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis
Berg, G., Barchuk, M., Lobo, M., & Nogueira, J. P. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102562 · Cited by 36
Berezhnoy, G., Laske, C., & Trautwein, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012472 · Cited by 31
“This variation warrants future investigations, as IDL phospholipids were also found to be elevated in a type 2 diabetes drug treatment study, suggesting a restored lipid metabolism in diabetes patients [44].”
BackgroundWharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02781-x · Cited by 26
Gallo, G., & Volpe, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052484 · Cited by 24
“In diabetic patients, GLP1-RAs have been shown to attenuate postprandial ApoB48 production and the clearance of triglyceride-rich chylomicrons [68].”
BackgroundUnravelling lipoprotein metabolism with stable isotopes: tracing the flow
Ying, Q., Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154887 · Cited by 21
Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
Vergès, B. L., Hassid, J., Rouland, A., Bouillet, B., Simoneau, I., Petit, J., & Duvillard, L. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101284 · Cited by 18
Self-citationRivera, F. B., Chin, M. N. C., Pine, P. L. S., Ruyeras, M. M. J., Galang, D. J. C., Gandionco, K. M., Morales, B. L. F. D., Climaco, Z. M. V., Bantayan, N. R. B., Magalong, J. V., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2442027 · Cited by 19
Wretlind, A., Curovic, V. R., de Zawadzki, A., Suvitaival, T., Xu, J., Zobel, E. H., von Scholten, B. J., Ripa, R. S., Kjær, A., Hansen, T. W., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01922-z · Cited by 21
“Furthermore, several studies reported improvements in lipoprotein profiles following treatment with liraglutide [55–58], indicating that its effects on the lipidome may not be limited to ceramides.”
BackgroundGLP-1 receptor agonists synergistic effects of metabolic reprogramming and cardioprotection
Wang, X., Qi, M., Yang, L., Yang, L., Wang, X., Zhang, F., Cui, Y., Wang, D., Wang, Y., & Lv, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1614726 · Cited by 20
Ekhzaimy, A. A., Masood, A., Benabdelkamel, H., Elhassan, T., Musambil, M., & Alfadda, A. A. (2022) · Diabetes and Vascular Disease Research · doi:10.1177/14791641221094322 · Cited by 16
Shi, R., Lu, Y., Liu, D., & Guo, Z. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01775-x · Cited by 13
“ApoB is the principal lipoprotein component of LDL-C [8], and abnormal metabolism of apoB is regarded as an important feature of diabetic dyslipidemia [9].”
BackgroundBułdak, Ł., Machnik, G., Skudrzyk, E., Bołdys, A., Maligłówka, M., Kosowski, M., Basiak, M., Bułdak, R. J., & Okopień, B. (2022) · Journal of Applied Biomedicine · doi:10.32725/jab.2022.015 · Cited by 15
Moreira, R. O., Valério, C. M., Hohl, A., Moulin, C., Moura, F., Trujilho, F. R., Gerchman, F., Corrêa, L. L., Mancini, M. C., de Melo, M. E., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0422 · Cited by 29
Insight into the role of PCSK9 in glucose metabolism
Xu, J., Wang, T., Shu, H., Shi, S., Tao, L., & Li, J. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117444 · Cited by 11
Stroke in the Patient With Type 2 Diabetes
Jerkins, T. W., & Bell, D. S. H. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.01.010 · Cited by 11
Chakravarthy, M. V., Elliott, M. A., Acosta, L., Sonnenberg, G. E., Bialonczyk, D., Wu, J., ARGÜELLES-TELLO, F. A., Garcia‐Reza, R., González‐González, J. G., Hansen, S. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70006 · Cited by 11
“33 GIP receptor agon-ism may also play a role in promoting lipid metabolism by increasing adipocyte lipoprotein lipase expression, enhancing blood flow to adipose tissue, and increasing uptake of triglycerides by adipose tissue.”
Lu, F., Li, E., & Yang, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19371 · Cited by 9
Lee, J., Li, Y., Cheng, J., Liu, I.-M., & Cheng, K. (2024) · Pharmaceuticals · doi:10.3390/ph17040538 · Cited by 7
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Vergès, B. L., Vantyghem, M., Reznik, Y., Duvillard, L., Rouland, A., Capel, É., & Vigouroux, C. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.320774 · Cited by 8
Self-citationTóth, L. I., Harsányi, A., Csiha, S., Molnár, Á., Lőrincz, H., Nagy, A. C., Paragh, G., Harangi, M., & Sztanek, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26135951 · Cited by 9
“The GLP-1 RA liraglutide has been demonstrated to exert a positive influence on LDL cholesterol and associated cardiovascular risk factors by diminishing oxidized LDL-induced endothelial dysfunction, enhancing dyslipidaemia, and augmenting the catabolism of apoB-containing lipoproteins [8,24].”
Wang, J.-K., Zhang, D., Wang, J.-F., Lu, W., Wang, J., Liang, S.-F., Liu, R., Jiang, J., Li, H., & Yang, X. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i1.99526 · Cited by 6
Wretlind, A., Zobel, E. H., de Zawadzki, A., Ripa, R. S., Curovic, V. R., von Scholten, B. J., Mattila, I. M., Hansen, T. W., Kjær, A., Vestergaard, H., et al. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.856485 · Cited by 4
Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism
Taskinen, M., Matikainen, N., Björnson, E., Söderlund, S., Ainola, M., Hakkarainen, A., Lundbom, N. M. I., Sihlbom, C., Thorsell, A., Andersson, L., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1187 · Cited by 4
“In a 75 pioneering study, exenatide was reported to reduce acutely apoB48 production in healthy humans 76 (15), and liraglutide appears to have a similar action in type 2 diabetic subjects (29-31).”
BackgroundLu, F., Li, E., Gao, Y., Zhang, Y., Kong, L., & Yang, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16202 · Cited by 4
Xiang, J., Dai, H., Hou, Y., Wang, Q., Wang, T., Li, M., Zhao, Z., Lu, J., Dai, M., Zhang, D., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.880467 · Cited by 3
“Liraglutide, one of the glucagon-like peptide-1 (GLP-1) analogs that could decrease post-prandial glucose level by regulating incretin in type 2 diabetes, reduced RBP4 gene expression in adipose tissue in mice, which might contribute to the reduction of cardiovascular risk in diabetes (24).”
BackgroundGhodsian, N., Abner, E., Emdin, C. A., Gobeil, É., Taba, N., Haas, M. E., Perrot, N., Manikpurage, H. D., Gagnon, É., Bourgault, J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3865274 · Cited by 3
The Impact of PCSK9 on Diabetic Cardiomyopathy: Mechanisms and Implications
Wang, H., Wang, P., Wang, Y., Du, S., Zhao, J., & Zhang, Z. (2025) · Biomolecules · doi:10.3390/biom15091240 · Cited by 3
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Self-citationRepetti, G. G., Abel, E. D., Tontonoz, P., & Sallam, T. (2026) · Circulation Research · doi:10.1161/circresaha.126.328680 · Cited by 3
Dyslipidemia in Metabolic Syndrome
Toh, S.-A. E. S., & Lee, M. H. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_58-1 · Cited by 4
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?
Alnima, T., Smits, M. M., & Hanssen, N. M. J. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000949 · Cited by 3
“The contribution of the lipid lowering by peptide-1 receptor agonists to apo-B100-containing lipoprotein catabolism [23].”
Hashim, A. A., Smaism, M. F., & Hassan, M. I. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns4.11114 · Cited by 2
Duvillard, L., de Barros, J.-P. P., Rouland, A., Simoneau, I., Denimal, D., Bouillet, B., Petit, J., & Vergès, B. L. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101535 · Cited by 1
Self-citationLipid metabolism disorders in metabolic syndrome
Polyakova, E. A. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6539 · Cited by 1
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101725 · Cited by 3
Self-citationZawadzki, M., & Karczewska‐Kupczewska, M. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/8388511 · Cited by 1
Dyslipidemia in Metabolic Syndrome
Toh, S.-A. E. S., & Lee, M. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_58 · Cited by 1
Ghodsian, N., Abner, E., Emdin, C. A., Gobeil, É., Taba, N., Haas, M. J., Perrot, N., Manikpurage, H. D., Gagnon, É., Bourgault, J., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-97977/v1 · Cited by 1
Nogueira, J. P., Vargas‐Uricoechea, H., & Navarrete, S. (2023) · Revista Colombiana de Cardiología · doi:10.24875/rccar.m23000216
AVC, nouveaux traitements : place des agonistes du récepteur du GLP-1
Vergès, B. L. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.07.005
Self-citationMalkani, K. V., Zhang, R., Sobti, N. K., Vadaketh, K., Groenendyk, J., Purkayastha, S., Ying, X., Newbury, D., Steitieh, D., Patel, S. A., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101318
“Ongoing trends in GLP-1 RA prescribing may therefore alter the landscape of lipid management and merit future study in relation to triglyceride-lowering agents [20,21].”
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Self-citationWretlind, A., Curovic, V. R., de Zawadzki, A., Suvitaival, T., Xu, J., Zobel, E. H., von Scholten, B. J., Ripa, R. S., Kjaer, A., Hansen, T. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26619862
Vergès, B. L. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)48948-8
Self-citationIncretin-based therapies: Effects on plasma lipids and potential mechanisms
Syed‐Abdul, M. M., & Lewis, G. F. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109057
Mikhael, F. G., Ayoub, C., Teperikidis, E., Biondi-Zoccai, G., Booz, G. W., Zouein, F. A., & Makarem, N. N. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01471-7
“…diabetes, liraglutide has been shown to increase the catabolism of apoB-100-containing lipoproteins across multiple subclasses, including IDL and LDL, and to reduce plasma apoB-100 levels, indicating enhanced lipoprotein clearance and decreased availability of apoB-100 for particle formation [32].”
Influential
Metadata
- Authors
- Vergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Petit, J. M., Degrace, P., & Demizieux, L.
- Affiliations
- Inserm (FR)
- INSERM LNC UMR1231, University of Burgundy, Dijon, France
- CHU Dijon Bourgogne (FR)
- Corresponding author
- Vergès, Bruno
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-02-02
- Volume
- 44
- Issue
- 4
- Pages
- 1027-1037
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3126193654
- Cited by
- 54
- References
- 45
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 8
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Agence Nationale de la Recherche (ANR-11-LABX-0021)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- apolipoprotein B-100, lipoprotein catabolism, type 2 diabetes, diabetic dyslipidemia, GLP-1 receptor agonists, PCSK9, VLDL, IDL, low-density lipoprotein, triglyceride-rich lipoproteins, small dense LDL, lipoprotein clearance, atherogenic dyslipidemia
- MeSH terms
- Liraglutide, Proprotein Convertase 9, Animals, Diabetes Mellitus, Type 2, Humans, Lipoproteins, Lipoproteins, LDL, Lipoproteins, VLDL, Subtilisins, Mice, Retinol-Binding Proteins, Plasma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.